文献速递消化系统肿瘤妇科肿瘤乳腺癌

多基因面板检测为林奇综合征提供新视角

Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
PubMed 文献 · J Clin Oncol · 2017-05-17

该研究回顾性分析了2012年3月至2015年6月间接受包含错配修复(MMR)和EPCAM基因的多基因面板检测的34981例患者,其中528例携带MMR突变。MSH6突变最常见,其次为PMS2、MSH2、MLH1和EPCAM。仅患乳腺癌者中MSH6和PMS2突变比MLH1和MSH2突变更常见(P=2.3×10⁻⁵),提示MSH6和PMS2突变个体可能表现为遗传性乳腺癌和卵巢癌表型。

要点

  • 在528例MMR突变携带者中,MSH6突变最常见,其次为PMS2、MSH2、MLH1和EPCAM突变。
  • 仅患乳腺癌者中MSH6和PMS2突变比MLH1和MSH2突变更常见(P=2.3×10⁻⁵)。
  • 22.2%的患者符合BRCA1/2检测标准但不符合LS检测标准,5.1%两者均不符合。

核心结论

  • 结果提示MSH6和PMS2突变个体可能表现为遗传性乳腺癌和卵巢癌表型。
  • 数据凸显当前检测标准在识别这些患者方面的局限性,以及需进一步研究MMR突变患者的癌症风险。

研究设计与样本

  • 回顾性综述2012年3月至2015年6月间接受多基因面板检测(包括MMR和EPCAM基因)的患者临床病史,共34981例,并进行系列统计比较。

主要发现

  • 在528例MMR突变患者中,MSH6突变最常见,其次为PMS2、MSH2、MLH1和EPCAM突变。
  • 528例中63例(11.9%)仅患乳腺癌,144例(27.3%)仅患结直肠癌。
  • 仅患乳腺癌者与仅患结直肠癌者相比,MSH6和PMS2突变比MLH1和MSH2突变更常见(P=2.3×10⁻⁵)。
  • 528例中22.2%符合BRCA1/2检测标准但不符合LS检测标准,5.1%两者均不符合。
  • 在符合BRCA1/2检测标准但不符合LS检测标准的患者中,MSH6和PMS2突变比MLH1和MSH2突变更常见(P=4.3×10⁻⁷)。

关键数值与推荐

  • 528例MMR突变患者中,仅患乳腺癌63例(11.9%),仅患结直肠癌144例(27.3%)。
  • 仅患乳腺癌者与仅患结直肠癌者相比,MSH6和PMS2突变比MLH1和MSH2突变更常见(P=2.3×10⁻⁵)。
  • 528例中22.2%符合BRCA1/2检测标准但不符合LS检测标准,5.1%两者均不符合。
  • 符合BRCA1/2检测标准但不符合LS检测标准的患者中,MSH6和PMS2突变比MLH1和MSH2突变更常见(P=4.3×10⁻⁷)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出当前检测标准在识别MSH6和PMS2突变患者方面存在局限性。
  • 原文提出需进一步研究MMR突变患者的癌症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Most existing literature describes Lynch syndrome (LS) as a hereditary syndrome leading to high risks of colorectal cancer (CRC) and endometrial cancer mainly as a result of mutations in MLH1 and MSH2. Most of these studies were performed on cohorts with disease suggestive of hereditary CRC and population-based CRC and endometrial cancer cohorts, possibly biasing results. We aimed to describe a large cohort of mismatch repair (MMR) mutation carriers ascertained through multigene panel testing, evaluate their phenotype, and compare the results with those of previous studies. Methods We retrospectively reviewed clinical histories of patients who had multigene panel testing, including the MMR and EPCAM genes, between March 2012 and June 2015 (N = 34,981) and performed a series of statistical comparisons. Results Overall, MSH6 mutations were most frequent, followed by PMS2, MSH2, MLH1, and EPCAM mutations, respectively. Of 528 patients who had MMR mutations, 63 (11.9%) had breast cancer only and 144 (27.3%) had CRC only. When comparing those with breast cancer only to those with CRC only, MSH6 and PMS2 mutations were more frequent than MLH1 and MSH2 mutations ( P = 2.3 × 10-5). Of the 528 patients, 22.2% met BRCA1 and BRCA2 ( BRCA1/2) testing criteria and not LS criteria, and 5.1% met neither BRCA1/2 nor LS testing criteria. MSH6 and PMS2 mutations were more frequent than MLH1 and MSH2 mutations among patients who met BRCA1/2 testing criteria but did not meet LS testing criteria ( P = 4.3 × 10-7). Conclusion These results provide a new perspective on LS and suggest that individuals with MSH6 and PMS2 mutations may present with a hereditary breast and ovarian cancer phenotype. These data also highlight the limitations of current testing criteria in identifying these patients, as well as the need for further investigation of cancer risks in patients with MMR mutations.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Espenschied CR, LaDuca H, Li S, et al. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome. J Clin Oncol. 2017. PMID: 28514183. doi:10.1200/JCO.2016.71.9260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。